瀏覽 Coursera 的全部課程

For Enterprise

Join for Free
Log In

艺术与人文
商务
计算机科学
数据科学
信息技术
健康
数学和逻辑
个人发展
物理科学与工程
社会科学
语言学习
學位
證書

瀏覽 Coursera 的全部課程

瀏覽
搜索
企業版
登錄
免費加入

4.2.3 Decision Models

Loading...

Medical Technology and Evaluation

明尼苏达大学

4.5（149 個評分） | 8.4K 名學生已註冊

課程 4（共 5 門，医疗市场專項課程）

Innovations in medical technologies are one of the leading areas of economic growth in the world. Whether new technologies take the form of pharmaceutical, medical device, biotechnology, information technology of some combination of these innovations, the opportunities for both private enterprise and social welfare are substantial. However, these innovations are not without cost, and require reimbursement from either a privately or publicly financed health care delivery system to enter the marketplace. This course aims to provide knowledge of the concepts, data, and methodology required to critically evaluate new medical technologies in order to secure financial investment, reimbursement, and regulatory compliance objectives, such as FDA approval. The course is designed to provide understanding of the analytic tools needed to evaluate medical technologies. After completing this course, students will have the skills needed to: - Understand the reimbursement systems financing medical technology use. - Understand the role of government and regulatory agencies in the development and use of new medical technologies. - Identify a population to be served by a medical technology. - Use health care data to evaluate a medical technology. - Perform cost/benefit and cost/effectiveness analysis of a new technology.

查看授課大綱

審閱

4.5（149 個評分）

5 stars
88 ratings
4 stars
47 ratings
3 stars
10 ratings
2 stars
2 ratings
1 star
2 ratings

FC

Jun 29, 2019

I liked this course... its very useful and 4 weeks of learning the medical technology and evaluation gave me a strength to find the aspects of modern medical technology.

RL

Mar 17, 2017

Who knew development of medical technology was scrutinized so much. Plus all the factors that are needed to be taken into account.

從本節課中

Methodological Approaches and Considerations

Module 4 brings everything together from the first three modules. We will go into more detail about some of the more common quantitative methodologies you may encounter with an evaluation. We will talk about incorporating the effects of uncertainty and time into a medical technology evaluation model as well as the type of models that allow for the dynamic nature of patient responses to medical technology.

4.2.1 Baye’s Rule7:42

4.2.2 Discounting6:59

4.2.3 Decision Models8:28

教學方

Eric Barrette
Director of Research

腳本

This is lesson 4.2.3, Decision Models.

Decision modelling is a means of incorporating probabilities and

future costs into a medical technology assessment.

Both base rule and discounting are tools that maybe useful for

calculating a decision model.

It is also possibly more useful to consider decision modelling in the case

of an example.

So consider a health care worker who has a needle-stick injury and whether or

not that health care worker should be given an HIV preventive treatment.

HIV is an incurable chronic illness, and

there is a risk of infection from a needle-stick injury.

Preventive treatment or prophylaxis treatment can be given to prevent HIV

infection, but there are many potential side effects and is not 100% effective.

Decision modeling is one means of determining whether or

not treatment is cost effective.

This slide exemplifies the decision model graphically.

The question being asked, should treatment be given?

Has two possible outcomes.

Yes, treatment should be given or no, treatment should not be given.

If treatment is given, there's a possibility of side effects but

there is also a possibility of no side effects.

In either case, because the treatment is not 100% effective,

there's also a probability of the healthcare worker still

getting HIV, or potentially not getting HIV.

If no treatment is given, there is also the probability of a healthcare worker

not getting HIV, but there is a possibility that they will get HIV.

All of these possibilities are depicted in this model.

In this case, the objective of our example technology assessment

is to determine if there are sufficient benefits to treatment for HIV for

the healthcare worker who has a needle-stick injury.

The relevant questions we need to address before beginning.

Our calculations are, what is the risk of infection after the needle-stick?

What drugs are available in order to prevent HIV?

How effective are those drugs?

What are their side effects?

And I would like to point out in this case,

we're not considering what any of the costs are.

But in a more robust model, we'd want to answer all these questions and

try to identify the cost associated with all of them.

Although we're not directly considering costs,

we are considering benefits and harms.

So if there's no treatment, there's no side effects, and

no unnecessary treatment.

However, there's still a risk of developing HIV.

If treatment is given, there's a reduced risk of HIV,

but there is also potential unnecessary treatment.

Because it's possible that the person would not have gotten HIV,

even without having received the treatment.

There's also the side effects from the treatment, and

after the treatment there's still a risk of developing HIV.

Note, this isn't no risk, it's a reduced risk.

Now that we've reviewed the types of information that's necessary to evaluate

the model, we can discuss how to evaluate the model.

To do so, we apply probabilities to each possibility in the decision model,

and the outcome measures to each end point.

At each split in the decision tree or each branch off of one of the previous events,

the probabilities have to add up to 100%.

Also note that the probabilities now come measures

should come good quality research evidence.

And if assumptions are made about any particular probability or

outcome it needs to be clear why and how those assumptions were made.

Finally, to calculate the outcomes or

the final measures used to evaluate the technology decision model.

The probabilities are multiplied by the outcome measures which

results in an expected value of the outcome measure.

For this example the average risk of HIV transmission after

exposure is approximately 0.3%.

The effectiveness of the treatment is difficult to estimate, but

there are some studies that have tried to do so.

One study found that it reduced the odds of HIV infection

by 81% which is equivalent to about a 5% chance of HIV.

Now, there was some calculation that was done to get from 81%

reduced odds ratio to a 5% chance.

It's important to know how and what types of information are reported in studies,

so that you don't blindly apply probabilities to the decision model that

aren't appropriate.

Finally, there's numerous side effects that include nausea and vomiting, fatigue,

headache, abdominal pain, diarrhea, and possibly others.

The probability of getting a side effect has a wide range of estimates,

anywhere between 50 and 75%.

So in order to estimate the model we'll assume it's around 63%.

Just as it we have to identify the probabilities for the model.

We also had to identify values of the outcomes.

We can do this also from the literature.

The existing preference scores associated with HIV infection and some side effects.

Or the quality of life measures include preference scores for

HIV which are between 0.5 and.0.75, and

preference scores for some of the side effects.

The values that we can apply to the model are shown below.

Note, whichever values we apply to the model

we still need to demonstrate where and how they came from.

So that anyone using the results of the model are able to assess the validity and

reliability of the model itself.

If we again consider the graphic representation of the model for

each possible outcome.

No treatment or yes treatment, we would assign a probability,

To each event occurring.

And note, Probabilities in each case have to add the one.

So the probability in first stag of 1 plus 2 has to equal 100%.

The same here and the same here, and the same here.

The outcome measures are then applied to

the end points where outcomes are assessed.

I've omitted the full calculations from this presentation.

However, the expected utility value of no treatment is 0.99715,

and the expected value of treatment is 0.9369.

Therefore, based on this model and

the assumptions made a person is better off with no treatment.

However, this could change if the assumptions, either the probabilities or

the outcome values, were changed.

It's important to remember that the assumptions made

in order to calculate the model impact the final results.

探索我們的目錄

免費加入並獲得個性化推薦、更新和優惠。

Coursera 致力於普及全世界最好的教育，它與全球一流大學和機構合作提供在線課程。

© 2019 Coursera Inc. 保留所有權利。

通過 App Store 下載

通過 Google Play 獲取

Coursera
關於
管理團隊
工作機會
目錄
證書
MasterTrack™ 證書
學位
企業版
政府版

社區
Learners
Partners
Developers
Beta Testers
Translators

連接
博客
Facebook
領英
Twitter
Instagram
YouTube
技術博客

更多
條款
隱私
幫助
內容訪問
媒體
聯繫我們
目錄
附屬公司